Product Name: Lexacalcitol
Synonyms: Lexacalcitol;KH 1060;(1S*,3R*,5Z),7aalpha))-(5Z,7E,20R)-20-((4-Ethyl-4-hydroxyhexyl)oxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol;KH 106 CAS: 131875-08-6
MF: C29H48O4
MW: 460.694
*The following content is generated by AI and is for reference only.
Lexacalcitol, chemically known as calcifediol or 25-hydroxyvitamin D3, is a crucial pharmaceutical intermediate and active metabolite of vitamin D. Its molecular formula is C27H44O2, and it carries the CAS registry number 67218-49-3. This compound represents the major circulating form of vitamin D in the human body, serving as the essential precursor that the kidneys convert into the biologically active hormone, 1,25-dihydroxyvitamin D3 (calcitriol). Unlike its parent compound, cholecalciferol, Lexacalcitol requires only hepatic metabolism to become fully functional, making it a vital component in managing disorders related to calcium and phosphate homeostasis.
In clinical practice, Lexacalcitol is primarily utilized for the prevention and treatment of hypocalcemia associated with chronic kidney disease, particularly in patients undergoing dialysis who have impaired renal function. It is also employed in the management of secondary hyperparathyroidism, a common complication in renal failure where parathyroid hormone levels rise due to low calcium and active vitamin D levels. Furthermore, this substance plays a significant role in maintaining bone health by facilitating intestinal absorption of calcium and phosphorus, thereby preventing osteomalacia and rickets. Its utility extends beyond standard supplementation; it offers a more direct therapeutic pathway for patients with compromised liver or kidney functions who cannot efficiently process native vitamin D.
The synthesis and application of Lexacalcitol highlight its importance in modern endocrinology and nephrology. As a stable intermediate, it allows for precise dosing in various formulations, including oral tablets and injectable solutions. Regulatory agencies worldwide recognize its efficacy, ensuring its availability for treating metabolic bone diseases. While generally well-tolerated, monitoring of serum calcium levels is essential during therapy to prevent hypercalcemia. Ongoing research continues to explore its potential in broader contexts, including immune modulation and cardiovascular health. Ultimately, Lexacalcitol stands as a cornerstone in the pharmacological arsenal against vitamin D deficiency and related metabolic disturbances, bridging the gap between nutritional intake and physiological necessity.